Open-Source Automated Insulin Delivery in Type 1 Diabetes

This multicenter, open label, randomized controlled trial evaluated the efficacy and safety of an open source automated insulin delivery (AID) system compared to sensor augmented insulin pump therapy (control) in patients with type 1 diabetes (ages 7–70). The AID system, a modified version of AndroidAPS 2.8 paired with a DANA i insulin pump and Dexcom G6 CGM, was tested over 24 weeks. The primary outcome was the percentage of time in the target glucose range (70–180 mg/dL). Results showed the AID group achieved a mean time in range of 71.2±12.1%, compared to 54.5±16.0% in the control group (adjusted difference: 14.0 percentage points; 95% CI, 9.2–18.8; P<0.001). No severe hypoglycemia or diabetic ketoacidosis occurred in either group. The study concluded that open-source AID systems significantly improve glycemic control in type 1 diabetes.

This multicenter, open label, randomized controlled trial evaluated the efficacy and safety of an open source automated insulin delivery (AID) system compared to sensor augmented insulin pump therapy (control) in patients with type 1 diabetes (ages 7–70). The AID system, a modified version of AndroidAPS 2.8 paired with a DANA i insulin pump and Dexcom G6 CGM, was tested over 24 weeks. The primary outcome was the percentage of time in the target glucose range (70–180 mg/dL). Results showed the AID group achieved a mean time in range of 71.2±12.1%, compared to 54.5±16.0% in the control group (adjusted difference: 14.0 percentage points; 95% CI, 9.2–18.8; P<0.001). No severe hypoglycemia or diabetic ketoacidosis occurred in either group. The study concluded that open-source AID systems significantly improve glycemic control in type 1 diabetes.